Stock Fundamentals

Company Information

Company Name
Takeda Pharmaceutical Co Ltd ADR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYSE
ISIN: US8740602052
CIK: 0001395064
CUSIP: 874060106
Currency: USD
Full Time Employees: 47,455
Phone: 81 3 3278-2111
Fiscal Year End: March
IPO Date: Oct 27, 2008
Description:

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Address:

1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668

Directors & Officers

Name Title Year Born
Mr. Christophe P. Weber President, CEO & Representative Director 1966
Mr. Milano Furuta CFO & Director 1978
Dr. Andrew S. Plump M.D., Ph.D. President of Research & Development and Representative Director 1965
Dr. Seigo Izumo Chair of Management Board NA
Mr. Haruhiko Hirate Member of Management Board 1957
Mr. Salvatore Alesci M.D., Ph.D. Member of Management Board and Head of R&D Global Science & Biomedical Policy 1975
Michael Fox Chief Operating Officer NA
Norimasa Takeda Chief Accounting Officer & Corporate Controller NA
Mr. Iwaaki Taniguchi Senior Vice President of Corporate Finance & Controlling Department NA
Mr. Gabriele Ricci Chief Data & Technology Officer 1978

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 24, 2024 Pharmaceutical Co Ltd Takeda N/A Sale 3.70M $8.10 $30.00M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Capital Research Global Investors 19.10M Mar 31, 2026 0.60% $0.05 41.65%
FMR Inc 7.12M Mar 31, 2026 0.23% $0.01 75.44%
Morgan Stanley - Brokerage Accounts 6.47M Mar 31, 2026 0.20% $0.01 1.51%
Adage Capital Partners Gp LLC 6.42M Mar 31, 2026 0.20% $0.18 0.00%
The Goldman Sachs Group Inc 5.62M Mar 31, 2026 0.18% $0.01 16.93%
Brandes Investment Partners & Co 4.43M Mar 31, 2026 0.14% $0.58 14.14%
BlackRock Inc 3.18M Mar 31, 2026 0.10% $0.00 16.28%
Arrowstreet Capital Limited Partnership 3.12M Mar 31, 2026 0.10% $0.03 -45.16%
Renaissance Technologies Corp 2.99M Mar 31, 2026 0.09% $0.09 14.16%
UBS Group AG 2.74M Mar 31, 2026 0.09% $0.01 -33.55%
D. E. Shaw & Co LP 2.60M Mar 31, 2026 0.08% $0.03 -39.39%
Van Eck Associates Corporation 2.26M Mar 31, 2026 0.07% $0.03 -1.96%
First Trust Advisors L.P. 1.97M Mar 31, 2026 0.06% $0.03 -17.27%
Northern Trust Corp 1.96M Mar 31, 2026 0.06% $0.00 15.43%
Managed Asset Portfolios, LLC 1.80M Mar 31, 2026 0.06% $3.99 20.23%
Quantinno Capital Management LP 1.29M Mar 31, 2026 0.04% $0.04 20.57%
Wells Fargo & Co 1.14M Mar 31, 2026 0.04% $0.00 7.13%
AQR Capital Management LLC 894.42K Mar 31, 2026 0.03% $0.01 31.67%
Capital Wealth Planning, LLC 886.84K Mar 31, 2026 0.03% $0.09 0.00%
Crossmark Global Holdings, Inc. 777.15K Mar 31, 2026 0.02% $0.21 4.29%

Shares Statistics

Shares Outstanding: 3.16B
Shares Float: 1.58B
% Insiders: 2.30%
% Institutions: 314.20%
Short % Float: 0.12%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 American Funds American Mutual A 18.16M 0.57% ▲ 40.89% Mar 31, 2026
2 Capital Group American Mutual Comp 18.16M 0.57% ▲ 40.89% Mar 31, 2026
3 First Trust Value Line® Dividend ETF 1.98M 0.06% ▼ 0.09% Apr 30, 2026
4 VanEck Pharmaceutical ETF 1.67M 0.05% ▲ 0.00% Apr 30, 2026
5 Amplify CWP International Enh Div IncETF 947.00K 0.03% ▲ 0.00% Apr 30, 2026
6 Capital Group American Mutual Trust U0 946.32K 0.03% ▲ 58.06% Mar 31, 2026
7 MAP Global Equity Composite 902.12K 0.03% ▲ 22.77% Mar 31, 2026
8 Steward Values Enhanced International I 711.87K 0.02% ▲ 0.00% Apr 30, 2026
9 Avantis International Equity ETF 485.24K 0.02% ▲ 0.00% Apr 30, 2026
10 MAP Global Balanced Composite 406.30K 0.01% ▲ 3.92% Mar 31, 2026

Valuation Metrics

Enterprise Value: $75.02B
Trailing P/E: 41.03
Forward P/E: 9.62

Financial Highlights

Market Cap: $47.96B
EBITDA: $1,346.40B
P/E Ratio: $41.03
PEG Ratio: $0.38
Book Value: $15.16
Dividend/Share: $200.00
Dividend Yield: 4.36%
Earnings/Share: $0.37
Profit Margin: 4.26%
Operating Margin: 3.09%
ROA (TTM): 2.63%
ROE (TTM): 2.61%
Revenue (TTM): $4,505.72B
Revenue/Share (TTM): $1.43K
Earnings Growth (YOY): 330.20%
Revenue Growth (YOY): 3.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2026-03-31 1.27x 0.07x 0.50x 1.51x 0.38x
2025-03-31 1.01x 0.65x 0.51x 2.49x 3.73x
2024-03-31 1.11x 0.67x 0.52x 201.49x 4.23x
2023-03-31 0.97x 0.69x 0.54x 4.19x 3.41x
2022-03-31 1.21x 0.76x 0.57x 3.76x 3.67x
2021-03-31 1.53x 0.90x 0.60x 3.89x 4.71x
2020-03-31 1.13x 1.08x 0.63x 68.84x 7.58x
2019-03-31 1.21x 1.11x 0.63x 4.26x 12.39x
2018-03-31 1.46x 0.49x 0.51x 7.57x 2.74x
2017-03-31 0.92x 0.60x 0.55x 6.70x 3.86x
2016-03-31 1.60x 0.12x 0.47x 4.10x 0.65x
2015-03-31 1.49x 0.05x 0.49x -3.93x 1.84x
2014-03-31 1.98x 0.06x 0.44x 4.53x 0.42x
2013-03-31 2.37x 0.00x 0.44x 36.87x 0.01x
2012-03-31 1.70x 0.12x 0.42x 140.75x 0.60x
2011-03-31 3.63x 0.00x 0.23x 274.97x 0.01x
2010-03-31 3.67x 0.00x 0.23x 294.06x 0.01x
2009-03-31 3.13x 0.00x 0.26x 189.06x 0.01x
2008-03-31 5.23x 0.00x 0.18x 1,270.64x 0.01x
2007-03-31 5.33x 0.00x 0.20x 1,856.28x 0.01x
2006-03-31 4.86x 0.00x 0.23x 1,103.59x 0.02x
2005-03-31 5.39x 0.01x 0.21x 1,153.53x 0.03x
2004-03-31 4.67x 0.01x 0.24x 1,035.19x 0.02x
2003-03-31 4.47x 0.00x 0.24x 739.73x 0.02x
2002-03-31 3.62x 0.01x 0.26x 370.54x 0.03x
2001-03-31 3.30x 0.01x 0.28x 221.67x 0.03x
2000-03-31 N/A N/A 0.00x 143.59x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TAK.US!